Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study

Abstract

Aim—To evaluate the cell proliferation activity in posterior uveal melanomas after Ru-106 brachytherapy and which had enough melanoma tissue to enable histological assessment, were included. The 57 eligible specimens were divided into a group of 44 eyes that were enucleated because of tumour regrowth, and a non-recurrent group of 13 eyes that were enucleated because of complications such as neovascular glaucoma. 46 non-irradiated eyes harbouring uveal melanoma served as a control group. All specimens underwent routine processing. They were cut into 5 µm sections, and were stained with two main cell proliferation markers: PC-10 for PCNA and MIB-1 for Ki-67. The stained sections were assessed, and the cells that were positive in the immunostaining were counted in each section. The results were evaluated by various statistical methods.

Results—The PC-10 score showed a statistically significant difference across the three groups (p = 0.002). The control group showed the highest PC-10 score (median 31.0 PCC/HPF) followed by the tumour regrowth group (median 4.9 PCC/HPF). The lowest PC-10 scores were found in the non-recurrent tumours (median 0.05 PCC/HPF). The MIB-1 score in the control group (median 5.77 PCC/HPF) was similar to the regrowth group (median 5.4 PCC/HPF). In contrast, the MIB-1 score in the non-recurrent tumours was statistically significantly lower (median 0.42 PCC/HPF). The PC-10 and MIB-1 scores were similar in tumours composed of either spindle cells or epithelioid cells in all groups.

Conclusions—The non-recurrent melanomas demonstrate significantly lower cellular proliferation activity than melanomas that showed regrowth or that were not irradiated at all. In our hands, PCNA gave more meaningful information than Ki-67. Our findings strongly support the need for treating regrowing posterior uveal melanoma either by enucleation or re-treatment by brachytherapy. On the other hand, also in the non-recurrent uveal melanomas there are viable cells with potential for proliferation, although fewer in number, with unknown capacity for metastatic spread. Therefore, the irradiated tumours should be followed for many years, probably for life.

The most common eye conserving way of treating posterior uveal melanoma is by radiotherapy. This is usually delivered by means of episcleral radioactive plaques. Cobalt-60,1 ruthenium-106,2 and iodine-1253 are the radioactive materials most commonly used. Other methods of radiotherapy of posterior uveal melanoma include teletherapy using charged particles of proton4 and helium ion beams5; recently, stereotactic radiosurgery using the Leksell gamma knife has been described as being efficient.6,7

After radiotherapy, most uveal melanomas show significant reduction in size, although complete disappearance is not common. Histological evaluation of residual tumours have demonstrated that most of the tumours harbour viable melanoma cells8–16 and some of these cells show proliferating activity using immunohistochemical markers.17–20

Previous studies have reported that between 6% to 34% of eyes treated for posterior uveal melanoma by radiotherapy are eventually enucleated, either because of regrowth of the tumour or because of complications caused by the radiotherapy, mainly secondary neovascular glaucoma.9–12

The purpose of the present multicentre, multinational study was to evaluate the cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy in eyes that were enucleated for various reasons. We have used two common cell proliferation markers, PC-10 for PCNA and MIB-1 for Ki-67. We also compared the findings in irradiated posterior uveal melanomas with those in tumours that were enucleated without being previously irradiated.

Methods

Eyes enucleated because of choroidal or ciliary body melanoma first treated with Ru-106 brachytherapy, and which had enough melanoma tissue to enable histological assessment, were included. Eyes that were enucleated after brachytherapy, but in which the primary method of treatment was unknown or in which histological sections did not contain...
enough tissue to enable reliable immunostaining, were excluded.

Tissue blocks from 143 cases of uveal melanoma were collected from the ophthalmic pathology laboratories of six European departments of ophthalmology. All eyes enucleated in these departments during the years 1980–97, after being previously treated with Ru-106 plaque brachytherapy for uveal melanoma, were evaluated for the study. Of the 143 specimens collected, 57 were included in the study. The other 86 tumours were excluded because the paraffin block did not contain sufficient residual tumour. Two groups were formed according to the indication for enucleation: the first included 44 eyes that were enucleated because of tumour regrowth after the brachytherapy; the second group included the remaining 13 eyes that were enucleated following brachytherapy due to complications such as glaucoma or a blind and painful eye without evidence of tumour regrowth—the non-recurrent group. Forty-six non-irradiated consecutive uveal melanomas were obtained from the ophthalmic pathology laboratory of the Hadassah University Hospital for use as the control group.

Table 1: Clinical and histological features of the uveal melanomas in the study

<table>
<thead>
<tr>
<th>Brachytherapy</th>
<th>Non-recurrent</th>
<th>Regrowth</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location</td>
<td>11/2</td>
<td>41/3</td>
<td>42/5</td>
</tr>
<tr>
<td>Tumour height (mm)(SD)</td>
<td>5.2 (3)</td>
<td>6 (3)</td>
<td>6.7 (3.4)</td>
</tr>
<tr>
<td>Largest tumour dimension (mm)(SD)</td>
<td>10 (2.3)</td>
<td>11.4 (4.5)</td>
<td>12.5 (3.9)</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>5/8</td>
<td>22/22</td>
<td>19/28</td>
</tr>
<tr>
<td>Age (years)(SD)</td>
<td>56 (12)</td>
<td>56 (14)</td>
<td>57 (12)</td>
</tr>
<tr>
<td>Cell type (number of tumours):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spindle</td>
<td>8</td>
<td>22</td>
<td>20</td>
</tr>
<tr>
<td>Epithelioid</td>
<td>3</td>
<td>20</td>
<td>26</td>
</tr>
<tr>
<td>Necrotic</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

Tumour location, height and largest tumour diameter were determined according to the histological sections after enucleation.

Figure 1: Box plot analyses of the proliferative activity of melanoma cells in the control, non-recurrent, and regrowth groups as estimated by PC-10 immunostaining. The thick horizontal lines show the median of the distribution of PC-10 positive cell count (PCC) per HPF; the boxes represent the interquartile range (IQR), and individual circles and asterisks represent outliers. A circle is more than 1.5 times IQR above the upper quartile, and an asterisk is more than three times IQR above the upper quartile.
applied (including multiple pairwise comparison). The distribution of each quantitative parameter was estimated by using the Kolmogorov-Smirnov test as well as the normal probability plot. When a parameter was not normally distributed the non-parametric Kruskal-Wallis ANOVA was used. MIB-1 and PC-10 readings were compared using the non-parametric Kruskal-Wallis ANOVA. If significance was found, multiple pairwise comparisons were performed using the Mann-Whitney non-parametric test with the Bonferroni correction for the significance level. The association between two qualitative parameters was tested using Fisher’s exact test.

**Results**

Tumour location, height, and diameter, patient age, sex, and cell type of the tumours are presented in Table 1. Except for cell type, there was no significant difference in these parameters across the three groups.

<table>
<thead>
<tr>
<th>Group/cell type</th>
<th>Median (range)</th>
<th>Median (range)</th>
<th>p Value (Mann-Whitney)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regrowth MIB-1</td>
<td>1.8 (0–48.8)</td>
<td>8.8 (0–48.15)</td>
<td>0.11</td>
</tr>
<tr>
<td>Regrowth PC-10</td>
<td>5.7 (0–88.4)</td>
<td>4.92 (0–157.6)</td>
<td>0.55</td>
</tr>
<tr>
<td>Non-recurrent MIB-1</td>
<td>0.7 (0–2.6)</td>
<td>0.15 (0–119.8)</td>
<td>1.0</td>
</tr>
<tr>
<td>Non-recurrent PC-10</td>
<td>0.32 (0–49.15)</td>
<td>0 (0–46.1)</td>
<td>0.397</td>
</tr>
<tr>
<td>Control MIB-1</td>
<td>5.82 (0–35.65)</td>
<td>6.05 (0–35.35)</td>
<td>0.942</td>
</tr>
<tr>
<td>Control PC-10</td>
<td>30 (0–202.05)</td>
<td>27.95 (0–145.75)</td>
<td>0.565</td>
</tr>
<tr>
<td>Total (all groups) MIB-1</td>
<td>1.12 (0–48.8)</td>
<td>6.07 (0–119.8)</td>
<td>0.221</td>
</tr>
<tr>
<td>Total (all groups) PC-10</td>
<td>4.35 (0–88.4)</td>
<td>1.97 (0–157.6)</td>
<td>0.195</td>
</tr>
</tbody>
</table>

**Discussion**

The diagnosis of uveal melanoma as well as the follow up of these tumours after conservative, usually irradiation, treatment, is done by non-invasive methods, mainly funduscopy and B-scan and A-scan ultrasonography. As opposed to most malignancies, in uveal melanoma we often do not have tissue diagnosis, and we do not have histological follow up of the residue of the tumour. The reason for this is the fear of spreading tumour cells beyond the

---

*www.bjophthalmol.com*
eye, through the site of a biopsy entrance or through tumour vessels damaged by the needle. By fundus examination we can see the reaction of the posterior uveal and MIB-1 to irradiation. Ultrasound examination, mainly the A-scan, guides us in evaluating the size of the tumour (mainly the height) and the internal reflectivity, which indicate tissue characteristics of the tumour. We usually view shrinkage in tumour size and increase of the internal reflectivity as indicators of success of the irradiation treatment.22

It is well known that most posterior melanomas do not disappear completely after irradiation treatment, but show significant reduction in size. The remnants of the tumours must be followed to detect regrowth indicating activation. Reduction in the tumour size and partial flattening have been shown to stabilise after about 2 years. However, as long as tumour remnants remain the tumour should be followed for possible regrowth.

All histological studies of uveal melanoma remnants show viable tumour cells, mainly of the spindle cell type.8–16 Moreover, cell proliferation has been found in several studies of irradiated tumours.17–20

Various methods have been used to assess cellular proliferation in uveal melanoma. Among them are counting of mitoses, measurement of DNA content by thymidine labelling, incorporation of thymidine analogue such as bromodeoxyuridine,21 flow cytometry,22 and assessment of silver stained nucleolar organiser regions. In recent years immunohistochemical markers, such as PCNA17–20 and Ki-67 have been used to examine cell proliferation in conventionally processed histological preparations. The markers seem to be reliable and easy tools for evaluating cellular activity.

In the present study we have used the two main proliferation markers, PC-10 for PCNA and MIB-1 for Ki-67, to evaluate the cell proliferation activity in posterior uveal melanomas after being treated by Ru-106 brachytherapy. We have studied two distinct groups of residual tumours: those which showed regrowth and actually failure of the treatment, and those that were enucleated because of post-irradiation complications. Because well controlled tumours did not always yield adequate tissue for study, our sample is overrepresented by regrowing tumours. We compared these groups with a control group of non-irradiated melanomas of similar sizes.

Both immunostainings demonstrated that the non-recurrent tumours had significantly lower cellular proliferation activity than the control group and the regrowth group. The regrowth group showed significantly less proliferative activity than the control group by PC-10 staining for PCNA. However, we could not show a difference between the control group and the regrowth group when we used the Ki-67 immunostaining. The reason for this may be manifold. Firstly, the Ki-67 and PCNA proteins are distinctly different cell cycle associated antigens. Secondly, the long half life of PCNA will in most cases generate a larger proportion of immunopositive cells than Ki-67. Compared with flow cytometry, PC-10 tends to overestimate and MIB-1 to underestimate cell proliferation. PC-10 will stain cells even after they have left the cell cycle, because of long half life. In this sense it is more “sensitive” to cells that are cycling or recently left the cell cycle. This also explains why more cells stain with PC-10 than with MIB-1.

This study is the first to compare the usefulness of these markers in uveal melanoma after failed brachytherapy. PC-10 was the only immunostaining to detect a difference between regrowing tumours and controls, owing to its higher sensitivity, and therefore in our hands it provides more meaningful information. Our results are comparable with previous studies that examined cell proliferation activities by one of the markers we used in our study.17–20 The measurements by both markers supplement each other and give a fuller picture than does either alone. Counting the number of tumours in which proliferating tumour cells were not detected, we found significantly more tumours with zero proliferating cells in the non-recurrent group. Also in this counting, the results with PCNA marker proved to be more meaningful. These results are also comparable with previous studies.17 19

It is obvious that clinically detectable regrowth of tumours indicate activity of the tumour, and our results are not surprising. Without having histological markers, ocular oncologists tend to enucleate or to re-treat regrowing uveal melanomas. Our findings strongly support this attitude, since regrowing melanomas may have a compartment of cycling cells as large as non-irradiated tumours, and since the presence of such proliferating cell population was previously shown to be associated with death from metastatic disease.25

On the other hand, we cannot ignore the apparent proliferating activity, although low, of part of the non-recurrent tumours that were enucleated because of ocular complications, the group that comprises the tumours that reacted well to irradiation. Apparently, these viable tumours remain a potential for later regrowth, and should be followed carefully for many years and probably for life. It remains unclear if these tumours, successfully treated by clinical standards, maintain a capacity for metastatic spread.

Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study

Jacob Pe'er, Fritz H Stefani, Stefan Seregard, Tero Kivela, Peter Lommatzsch, Jan U Prause, Beate Sobottka, Bertil Damato and Itay Chowers

Br J Ophthalmol 2001 85: 1208-1212
doi: 10.1136/bjo.85.10.1208

Updated information and services can be found at:
http://bjo.bmj.com/content/85/10/1208

These include:

References
This article cites 24 articles, 5 of which you can access for free at:
http://bjo.bmj.com/content/85/10/1208#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Angle (1006)
Glaucoma (988)
Intraocular pressure (1002)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/